Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali 11-jild 1-son (2026)
RESULTS OF THE USE OF EMICIZUMAB IN PATIENTS WITH HEMOPHILIA A – A PILOT SINGLE-CENTER STUDY
ИБРАГИМОВА Сапура Захидовна, АЛМЕДОВА Наргиза Нигматжоновна, БОТИРОВ Мирзохид Мансуржон угли, ШАДИБЕКОВА Оксана Борисовна, АРИПОВА Назокат Баходировна, ЕРИМБЕТОВА Индира Оралбаевна
Annotatsiya
Ibragimova Sapura Zakhidovna, Almedova Nargiza Nigmatjonovna, Botirov Mirzokhid Mansurzhon Ugli, Shadibekova Oksana Borisovna, Aripova Nazokat Bahodirovna, Erimbetova Indira Oralbaevna. Results of the use of emicizumab in patients with hemophilia A – a pilot single-center study // Journal of Biomedicine and Practice. 2026, vol. 11, issue 1. Resume. It is known that patients with severe hemophilia A, a hereditary bleeding disorder caused by a deficiency of coagulation factor VIII, often experience uncontrolled bleeding, which occurs despite the administration of prophylactic replacement therapy with coagulation factors. Such conditions are characteristic of the inhibitor form of hemophilia A [1,2]. An inhibitor is a polyclonal high-affinity IgG antibody that specifically neutralizes the procoagulant activity of coagulation factors, making bleeding management difficult. The emergence of inhibitors is associated with a worsening prognosis: a higher incidence of bleeding, accelerated development of arthropathy, and a decrease in quality of life. In more severe cases, this could lead to the death of children [3,6]. In order to prevent the above-mentioned conditions, improve the quality of life of patients and prevent complications of the disease, the Scientific and Practical Medical Center for Pediatric Hematology, Oncology and Immunology used the "Hemlibra" (emicizumab) in 15 children with hereditary bleeding disorder caused by the inhibitory form of coagulation factor VIII deficiency.
эмицизумаб, гемофилия А, фактор свёртывания крови VIII, ингибитор фактора свёртывания крови VIII, одностадийный клоттинговый метод, хромогенный методemicizumab, hemophilia A, coagulation factor VIII, coagulation factor VIII inhibitor, one-step clotting method, chromogenic methodemizizumab, gemofiliya A, VIII omil, VIII omil ingibitori, bir bosqichli ivish usuli, xromogen usul
Metadata manbasi: jurnal OAI-PMH arxivi · Sindex toʻliq matnni saqlamaydi, manbaga havola beradi.